These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10586345)

  • 1. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.
    Korte W; Jost C; Cogliatti S; Hess U; Cerny T
    Ann Oncol; 1999 Oct; 10(10):1249-50. PubMed ID: 10586345
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
    Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
    Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in CD20 positive multiple myeloma.
    Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau JL; Bataille R;
    Leukemia; 2007 Apr; 21(4):835-6. PubMed ID: 17268523
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab in CD20 positive multiple myeloma.
    Bergua JM; Cabrera C; Arteta EG; Prieto J
    Leukemia; 2008 May; 22(5):1082-3. PubMed ID: 17972949
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
    Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
    Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG.
    Saikia TK; Menon H; Advani SH
    Ann Oncol; 2001 Oct; 12(10):1493-4. PubMed ID: 11762825
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to 'Rituximab activity in CD20-positive multiple myeloma'.
    Gozzetti A; Fabbri A; Lazzi S; Bocchia M; Lauria F
    Leukemia; 2008 May; 22(5):1083; author reply 1083-4. PubMed ID: 17972948
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma.
    Hofer S; Hunziker S; Dirnhofer S; Ludwig C
    Br J Haematol; 2003 Aug; 122(4):690-1. PubMed ID: 12899729
    [No Abstract]   [Full Text] [Related]  

  • 9. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
    Boye J; Elter T; Engert A
    Ann Oncol; 2003 Apr; 14(4):520-35. PubMed ID: 12649096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
    Baz R; Fanning S; Kunkel L; Gaballa S; Karam MA; Reed J; Kelly M; Hussein M
    Leuk Lymphoma; 2007 Dec; 48(12):2338-44. PubMed ID: 18067008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
    Kollmar O; Becker S; Schilling MK; Maurer CA
    Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
    [No Abstract]   [Full Text] [Related]  

  • 12. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
    Treon SP; Pilarski LM; Belch AR; Kelliher A; Preffer FI; Shima Y; Mitsiades CS; Mitsiades NS; Szczepek AJ; Ellman L; Harmon D; Grossbard ML; Anderson KC
    J Immunother; 2002; 25(1):72-81. PubMed ID: 11924912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: therapeutic benefit! Vitamin R?
    Mo C; Vire B; Wiestner A
    Semin Hematol; 2010 Apr; 47(2):105-6. PubMed ID: 20350656
    [No Abstract]   [Full Text] [Related]  

  • 14. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation.
    Musto P; Carella AM; Greco MM; Falcone A; Sanpaolo G; Bodenizza C; Cascavilla N; Melillo L; Carella AM
    Br J Haematol; 2003 Nov; 123(4):746-7. PubMed ID: 14616983
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
    Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
    Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term response to maintenance treatment with rituximab in CD20(+) multiple myeloma.
    Ohno H
    Leuk Lymphoma; 2010 Nov; 51(11):2144-6. PubMed ID: 20807088
    [No Abstract]   [Full Text] [Related]  

  • 17. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
    Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L
    Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626
    [No Abstract]   [Full Text] [Related]  

  • 18. Daratumumab for the Treatment of Multiple Myeloma.
    Plesner T; Krejcik J
    Front Immunol; 2018; 9():1228. PubMed ID: 29915586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Loss of CD20 expression following rituximab-combined chemotherapy in CD20-positive and CyclinD1-positive multiple myeloma].
    Shiratori S; Kondo T; Kubota K; Wakasa K; Ibata M; Shono Y; Takahata M; Shigematu A; Kato N; Ota S; Tanaka J; Matsuno Y; Asaka M; Imamura M
    Rinsho Ketsueki; 2008 Nov; 49(11):1536-40. PubMed ID: 19047784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.